RU2759998C2 - Лечение глаукомы - Google Patents
Лечение глаукомы Download PDFInfo
- Publication number
- RU2759998C2 RU2759998C2 RU2019136633A RU2019136633A RU2759998C2 RU 2759998 C2 RU2759998 C2 RU 2759998C2 RU 2019136633 A RU2019136633 A RU 2019136633A RU 2019136633 A RU2019136633 A RU 2019136633A RU 2759998 C2 RU2759998 C2 RU 2759998C2
- Authority
- RU
- Russia
- Prior art keywords
- dextran sulfate
- glaucoma
- pharmaceutically acceptable
- acceptable salt
- subject
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 94
- 238000011282 treatment Methods 0.000 title claims abstract description 76
- 229960000633 dextran sulfate Drugs 0.000 claims abstract description 246
- 230000004410 intraocular pressure Effects 0.000 claims abstract description 92
- 150000003839 salts Chemical class 0.000 claims abstract description 79
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims abstract description 42
- 206010030043 Ocular hypertension Diseases 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 34
- 230000005764 inhibitory process Effects 0.000 claims abstract description 25
- 230000002207 retinal effect Effects 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 230000002265 prevention Effects 0.000 claims abstract description 17
- 210000004126 nerve fiber Anatomy 0.000 claims abstract description 15
- 210000003994 retinal ganglion cell Anatomy 0.000 claims abstract description 15
- 201000006366 primary open angle glaucoma Diseases 0.000 claims description 27
- 230000002401 inhibitory effect Effects 0.000 claims description 23
- 238000001990 intravenous administration Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 238000007920 subcutaneous administration Methods 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 10
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 239000011593 sulfur Substances 0.000 claims description 8
- 238000005481 NMR spectroscopy Methods 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000007910 systemic administration Methods 0.000 claims description 4
- 230000004493 normal intraocular pressure Effects 0.000 claims description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical group CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims 1
- 229920003045 dextran sodium sulfate Polymers 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 37
- 229940079593 drug Drugs 0.000 abstract description 23
- 230000006378 damage Effects 0.000 abstract description 12
- 230000009467 reduction Effects 0.000 abstract description 11
- 230000000324 neuroprotective effect Effects 0.000 abstract description 9
- 230000034994 death Effects 0.000 abstract description 8
- 208000034038 Pathologic Neovascularization Diseases 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 210000001508 eye Anatomy 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 47
- 238000000034 method Methods 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 32
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 30
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 27
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 27
- 239000011780 sodium chloride Substances 0.000 description 26
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 26
- 210000004116 schwann cell Anatomy 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 22
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- 230000037390 scarring Effects 0.000 description 19
- 230000006698 induction Effects 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 17
- 210000001585 trabecular meshwork Anatomy 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 210000001525 retina Anatomy 0.000 description 16
- 201000004569 Blindness Diseases 0.000 description 14
- 102100035784 Decorin Human genes 0.000 description 14
- 108090000738 Decorin Proteins 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 230000007423 decrease Effects 0.000 description 14
- 230000004393 visual impairment Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- -1 0.9% saline NaCl Chemical compound 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 11
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 11
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 11
- 206010016654 Fibrosis Diseases 0.000 description 11
- 108010085895 Laminin Proteins 0.000 description 11
- 102000007547 Laminin Human genes 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 230000004761 fibrosis Effects 0.000 description 11
- 238000003364 immunohistochemistry Methods 0.000 description 11
- 102100037362 Fibronectin Human genes 0.000 description 10
- 108090001090 Lectins Proteins 0.000 description 10
- 102000004856 Lectins Human genes 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 210000001723 extracellular space Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 238000012014 optical coherence tomography Methods 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 108010067306 Fibronectins Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000033115 angiogenesis Effects 0.000 description 8
- 210000002744 extracellular matrix Anatomy 0.000 description 8
- 238000013534 fluorescein angiography Methods 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 210000001742 aqueous humor Anatomy 0.000 description 7
- 230000009087 cell motility Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 7
- 231100000241 scar Toxicity 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010029113 Neovascularisation Diseases 0.000 description 6
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 6
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 210000003050 axon Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 210000003161 choroid Anatomy 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000001328 optic nerve Anatomy 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010064930 age-related macular degeneration Diseases 0.000 description 5
- 238000003491 array Methods 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000006727 cell loss Effects 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 4
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229960002303 citric acid monohydrate Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 239000003889 eye drop Substances 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000037387 scars Effects 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000219726 Griffonia simplicifolia Species 0.000 description 3
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 3
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 206010047571 Visual impairment Diseases 0.000 description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000037354 amino acid metabolism Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 238000000149 argon plasma sintering Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000008614 cellular interaction Effects 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002900 effect on cell Effects 0.000 description 3
- 230000000893 fibroproliferative effect Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000002430 laser surgery Methods 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 208000018769 loss of vision Diseases 0.000 description 3
- 231100000864 loss of vision Toxicity 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004879 molecular function Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000003733 optic disk Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000001023 pro-angiogenic effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000001210 retinal vessel Anatomy 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- 210000003786 sclera Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 208000029257 vision disease Diseases 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010071289 Factor XIII Proteins 0.000 description 2
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 2
- 101001095308 Homo sapiens Periostin Proteins 0.000 description 2
- 101000598025 Homo sapiens Talin-1 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 102000048238 Neuregulin-1 Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100037765 Periostin Human genes 0.000 description 2
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 2
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101150111584 RHOA gene Proteins 0.000 description 2
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 102100036977 Talin-1 Human genes 0.000 description 2
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 2
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000001775 bruch membrane Anatomy 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 210000004240 ciliary body Anatomy 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 210000000695 crystalline len Anatomy 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000000554 iris Anatomy 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 108010057670 laminin 1 Proteins 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000001259 mesencephalon Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 239000012120 mounting media Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 108091008695 photoreceptors Proteins 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000013120 recombinational repair Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- AVTLBBWTUPQRAY-UHFFFAOYSA-N 2-(2-cyanobutan-2-yldiazenyl)-2-methylbutanenitrile Chemical compound CCC(C)(C#N)N=NC(C)(CC)C#N AVTLBBWTUPQRAY-UHFFFAOYSA-N 0.000 description 1
- 102100040842 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase FUT3 Human genes 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102100035277 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6 Human genes 0.000 description 1
- 102100027271 40S ribosomal protein SA Human genes 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- 102100022734 Acyl carrier protein, mitochondrial Human genes 0.000 description 1
- 102100029374 Adapter molecule crk Human genes 0.000 description 1
- 102100032605 Adhesion G protein-coupled receptor B1 Human genes 0.000 description 1
- 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 description 1
- 102100031786 Adiponectin Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100038568 Age-related maculopathy susceptibility protein 2 Human genes 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 102100021333 Alpha-(1,3)-fucosyltransferase 7 Human genes 0.000 description 1
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 102100040409 Ameloblastin Human genes 0.000 description 1
- 102100034594 Angiopoietin-1 Human genes 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 102100031323 Anthrax toxin receptor 1 Human genes 0.000 description 1
- 102100033648 Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 3 Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102100035730 B-cell receptor-associated protein 31 Human genes 0.000 description 1
- 102100028239 Basal cell adhesion molecule Human genes 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 102100028625 Brain-specific homeobox protein homolog Human genes 0.000 description 1
- 102100028237 Breast cancer anti-estrogen resistance protein 1 Human genes 0.000 description 1
- 102100040843 C-type lectin domain family 4 member M Human genes 0.000 description 1
- 102100031168 CCN family member 2 Human genes 0.000 description 1
- 102100025215 CCN family member 5 Human genes 0.000 description 1
- 102100021992 CD209 antigen Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 102000053028 CD36 Antigens Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108091011896 CSF1 Proteins 0.000 description 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 1
- 102100024155 Cadherin-11 Human genes 0.000 description 1
- 102100024154 Cadherin-13 Human genes 0.000 description 1
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100027473 Cartilage oligomeric matrix protein Human genes 0.000 description 1
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
- 108010031504 Crk Associated Substrate Protein Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 108010076010 Cystathionine beta-lyase Proteins 0.000 description 1
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 description 1
- 102100039061 Cytokine receptor common subunit beta Human genes 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine group Chemical group N[C@H](CCCCN)C(=O)O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 1
- 102100031597 Dedicator of cytokinesis protein 2 Human genes 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 102100034578 Desmoglein-2 Human genes 0.000 description 1
- 102100034573 Desmoglein-4 Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 description 1
- 102100028572 Disabled homolog 2 Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100039673 Disintegrin and metalloproteinase domain-containing protein 10 Human genes 0.000 description 1
- 102100031113 Disintegrin and metalloproteinase domain-containing protein 15 Human genes 0.000 description 1
- 102100025682 Dystroglycan 1 Human genes 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 102100035813 E3 ubiquitin-protein ligase CBL Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 102100021579 Enhancer of filamentation 1 Human genes 0.000 description 1
- 102000050554 Eph Family Receptors Human genes 0.000 description 1
- 108091008815 Eph receptors Proteins 0.000 description 1
- 102100021601 Ephrin type-A receptor 8 Human genes 0.000 description 1
- 102100030779 Ephrin type-B receptor 1 Human genes 0.000 description 1
- 102000020086 Ephrin-A1 Human genes 0.000 description 1
- 108010043945 Ephrin-A1 Proteins 0.000 description 1
- 102000006397 Ephrin-B1 Human genes 0.000 description 1
- 108010044099 Ephrin-B1 Proteins 0.000 description 1
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 description 1
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101000823089 Equus caballus Alpha-1-antiproteinase 1 Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100040684 Fermitin family homolog 2 Human genes 0.000 description 1
- 102100031509 Fibrillin-1 Human genes 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100028065 Fibulin-5 Human genes 0.000 description 1
- 102100024521 Ficolin-2 Human genes 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102000000802 Galectin 3 Human genes 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102100021223 Glucosidase 2 subunit beta Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 102100030483 Histatin-1 Human genes 0.000 description 1
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 description 1
- 101000893701 Homo sapiens 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase FUT3 Proteins 0.000 description 1
- 101001022175 Homo sapiens 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6 Proteins 0.000 description 1
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000730039 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 9 Proteins 0.000 description 1
- 101000678845 Homo sapiens Acyl carrier protein, mitochondrial Proteins 0.000 description 1
- 101000919320 Homo sapiens Adapter molecule crk Proteins 0.000 description 1
- 101000796780 Homo sapiens Adhesion G protein-coupled receptor B1 Proteins 0.000 description 1
- 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 description 1
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 1
- 101000808726 Homo sapiens Age-related maculopathy susceptibility protein 2 Proteins 0.000 description 1
- 101000819497 Homo sapiens Alpha-(1,3)-fucosyltransferase 7 Proteins 0.000 description 1
- 101000951392 Homo sapiens Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Proteins 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000891247 Homo sapiens Ameloblastin Proteins 0.000 description 1
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- 101000796095 Homo sapiens Anthrax toxin receptor 1 Proteins 0.000 description 1
- 101000733571 Homo sapiens Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 3 Proteins 0.000 description 1
- 101000874270 Homo sapiens B-cell receptor-associated protein 31 Proteins 0.000 description 1
- 101000935638 Homo sapiens Basal cell adhesion molecule Proteins 0.000 description 1
- 101001000001 Homo sapiens Basement membrane-specific heparan sulfate proteoglycan core protein Proteins 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 1
- 101000695012 Homo sapiens Brain-specific homeobox protein homolog Proteins 0.000 description 1
- 101000766294 Homo sapiens Branched-chain-amino-acid aminotransferase, mitochondrial Proteins 0.000 description 1
- 101000749311 Homo sapiens C-type lectin domain family 4 member M Proteins 0.000 description 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
- 101000934220 Homo sapiens CCN family member 5 Proteins 0.000 description 1
- 101000897416 Homo sapiens CD209 antigen Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000762236 Homo sapiens Cadherin-11 Proteins 0.000 description 1
- 101000762243 Homo sapiens Cadherin-13 Proteins 0.000 description 1
- 101000793651 Homo sapiens Calreticulin Proteins 0.000 description 1
- 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 101001000206 Homo sapiens Decorin Proteins 0.000 description 1
- 101000866237 Homo sapiens Dedicator of cytokinesis protein 2 Proteins 0.000 description 1
- 101000924314 Homo sapiens Desmoglein-2 Proteins 0.000 description 1
- 101000924320 Homo sapiens Desmoglein-4 Proteins 0.000 description 1
- 101000915391 Homo sapiens Disabled homolog 2 Proteins 0.000 description 1
- 101000959356 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 10 Proteins 0.000 description 1
- 101000777455 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 15 Proteins 0.000 description 1
- 101000756727 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 23 Proteins 0.000 description 1
- 101000855983 Homo sapiens Dystroglycan 1 Proteins 0.000 description 1
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000898310 Homo sapiens Enhancer of filamentation 1 Proteins 0.000 description 1
- 101000898676 Homo sapiens Ephrin type-A receptor 8 Proteins 0.000 description 1
- 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 description 1
- 101000892677 Homo sapiens Fermitin family homolog 2 Proteins 0.000 description 1
- 101000846893 Homo sapiens Fibrillin-1 Proteins 0.000 description 1
- 101001060252 Homo sapiens Fibulin-5 Proteins 0.000 description 1
- 101001052753 Homo sapiens Ficolin-2 Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101001040875 Homo sapiens Glucosidase 2 subunit beta Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 description 1
- 101001082500 Homo sapiens Histatin-1 Proteins 0.000 description 1
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 101000599453 Homo sapiens Importin-9 Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 description 1
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 description 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
- 101001015059 Homo sapiens Integrin beta-5 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000599858 Homo sapiens Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 101000960337 Homo sapiens Intercellular adhesion molecule 5 Proteins 0.000 description 1
- 101001046633 Homo sapiens Junctional adhesion molecule A Proteins 0.000 description 1
- 101000611240 Homo sapiens Low molecular weight phosphotyrosine protein phosphatase Proteins 0.000 description 1
- 101001056128 Homo sapiens Mannose-binding protein C Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 1
- 101100241084 Homo sapiens NRTN gene Proteins 0.000 description 1
- 101000896414 Homo sapiens Nuclear nucleic acid-binding protein C1D Proteins 0.000 description 1
- 101000730665 Homo sapiens Phospholipase D1 Proteins 0.000 description 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 101001117519 Homo sapiens Prostaglandin E2 receptor EP2 subtype Proteins 0.000 description 1
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 description 1
- 101001026854 Homo sapiens Protein kinase C delta type Proteins 0.000 description 1
- 101000702384 Homo sapiens Protein sprouty homolog 2 Proteins 0.000 description 1
- 101000666171 Homo sapiens Protein-glutamine gamma-glutamyltransferase 2 Proteins 0.000 description 1
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 1
- 101000775749 Homo sapiens Proto-oncogene vav Proteins 0.000 description 1
- 101000655540 Homo sapiens Protransforming growth factor alpha Proteins 0.000 description 1
- 101001130458 Homo sapiens Ras-related protein Ral-B Proteins 0.000 description 1
- 101000695844 Homo sapiens Receptor-type tyrosine-protein phosphatase zeta Proteins 0.000 description 1
- 101000881168 Homo sapiens SPARC Proteins 0.000 description 1
- 101100311211 Homo sapiens STARD13 gene Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 101000820700 Homo sapiens Switch-associated protein 70 Proteins 0.000 description 1
- 101000692107 Homo sapiens Syndecan-3 Proteins 0.000 description 1
- 101000633605 Homo sapiens Thrombospondin-2 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000835083 Homo sapiens Tissue factor pathway inhibitor 2 Proteins 0.000 description 1
- 101000651211 Homo sapiens Transcription factor PU.1 Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 101000894525 Homo sapiens Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 description 1
- 101001026790 Homo sapiens Tyrosine-protein kinase Fes/Fps Proteins 0.000 description 1
- 101001022129 Homo sapiens Tyrosine-protein kinase Fyn Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 101000860430 Homo sapiens Versican core protein Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 1
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037961 Importin-9 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100025323 Integrin alpha-1 Human genes 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102100032819 Integrin alpha-3 Human genes 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 102100032816 Integrin alpha-6 Human genes 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- 102100033010 Integrin beta-5 Human genes 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 101150069749 Ipo9 gene Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102100022304 Junctional adhesion molecule A Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 102100034710 Laminin subunit gamma-1 Human genes 0.000 description 1
- 101710197072 Lectin 1 Proteins 0.000 description 1
- 101000964266 Loxosceles laeta Dermonecrotic toxin Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100026553 Mannose-binding protein C Human genes 0.000 description 1
- 102100039373 Membrane cofactor protein Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 102100021584 Neurturin Human genes 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 102100040557 Osteopontin Human genes 0.000 description 1
- 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 description 1
- 101150084398 PTAFR gene Proteins 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
- 102100039277 Pleiotrophin Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 1
- 101150008375 Pou4f1 gene Proteins 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 102100024448 Prostaglandin E2 receptor EP2 subtype Human genes 0.000 description 1
- 102100035251 Protein C-ets-1 Human genes 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100037340 Protein kinase C delta type Human genes 0.000 description 1
- 102100030400 Protein sprouty homolog 2 Human genes 0.000 description 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 1
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
- 102100032190 Proto-oncogene vav Human genes 0.000 description 1
- 102100032350 Protransforming growth factor alpha Human genes 0.000 description 1
- VSWDORGPIHIGNW-UHFFFAOYSA-N Pyrrolidine dithiocarbamic acid Chemical compound SC(=S)N1CCCC1 VSWDORGPIHIGNW-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 102100033135 RNA-binding protein with multiple splicing Human genes 0.000 description 1
- 101710140071 RNA-binding protein with multiple splicing Proteins 0.000 description 1
- 102100033982 Ran-binding protein 9 Human genes 0.000 description 1
- 102100031425 Ras-related protein Ral-B Human genes 0.000 description 1
- 102100028508 Receptor-type tyrosine-protein phosphatase zeta Human genes 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 102100027611 Rho-related GTP-binding protein RhoB Human genes 0.000 description 1
- 101150054980 Rhob gene Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102100037599 SPARC Human genes 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
- 102100025252 StAR-related lipid transfer protein 13 Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100021701 Switch-associated protein 70 Human genes 0.000 description 1
- 102100026084 Syndecan-3 Human genes 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- 102100029529 Thrombospondin-2 Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 102100026134 Tissue factor pathway inhibitor 2 Human genes 0.000 description 1
- 102100027654 Transcription factor PU.1 Human genes 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 description 1
- 102100022387 Transforming protein RhoA Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 102100027881 Tumor protein 63 Human genes 0.000 description 1
- 101710140697 Tumor protein 63 Proteins 0.000 description 1
- 102100037333 Tyrosine-protein kinase Fes/Fps Human genes 0.000 description 1
- 102100035221 Tyrosine-protein kinase Fyn Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 101150030763 Vegfa gene Proteins 0.000 description 1
- 102100028437 Versican core protein Human genes 0.000 description 1
- 102100033637 Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1 Human genes 0.000 description 1
- 101710141122 Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1 Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000026925 anterograde axon cargo transport Effects 0.000 description 1
- 230000000434 anti-fibrogenic effect Effects 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 batimastat Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010002974 benzyloxycarbonylleucyl-leucyl-leucine aldehyde Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 description 1
- 108091006374 cAMP receptor proteins Proteins 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 108091000114 ceramide glucosyltransferase Proteins 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 208000029436 dilated pupil Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940105546 durapatite Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 201000004949 exfoliation syndrome Diseases 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960002143 fluorescein Drugs 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000004914 glial activation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010090909 laminin gamma 1 Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000023578 negative regulation of cell adhesion Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000003977 optic chiasm Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 201000000041 pigment dispersion syndrome Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 102000030769 platelet activating factor receptor Human genes 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 101150010582 ranbp9 gene Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001116 retinal neuron Anatomy 0.000 description 1
- 230000009844 retrograde axon cargo transport Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 108091005418 scavenger receptor class E Proteins 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 229940072041 transforming growth factor beta 2 Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1750615 | 2017-05-17 | ||
| SE1750615-5 | 2017-05-17 | ||
| US201762555848P | 2017-09-08 | 2017-09-08 | |
| US62/555,848 | 2017-09-08 | ||
| PCT/SE2018/050506 WO2018212708A1 (en) | 2017-05-17 | 2018-05-16 | Treatment of glaucoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019136633A RU2019136633A (ru) | 2021-06-17 |
| RU2019136633A3 RU2019136633A3 (https=) | 2021-06-17 |
| RU2759998C2 true RU2759998C2 (ru) | 2021-11-22 |
Family
ID=62245395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019136633A RU2759998C2 (ru) | 2017-05-17 | 2018-05-16 | Лечение глаукомы |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11291684B2 (https=) |
| EP (1) | EP3532072B1 (https=) |
| JP (1) | JP6817466B2 (https=) |
| KR (1) | KR102331421B1 (https=) |
| CN (1) | CN110621320B (https=) |
| CA (1) | CA3063851C (https=) |
| DK (1) | DK3532072T3 (https=) |
| ES (1) | ES2777836T3 (https=) |
| IL (1) | IL270362B (https=) |
| PL (1) | PL3532072T3 (https=) |
| PT (1) | PT3532072T (https=) |
| RU (1) | RU2759998C2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3074987A1 (en) * | 2017-09-08 | 2019-03-14 | Tx Medic Ab | New use of dextran sulfate |
| GB202008919D0 (en) * | 2020-06-11 | 2020-07-29 | Univ Birmingham | Polysaccharide conpositions and therapeutic gels |
| CN115531417B (zh) * | 2022-11-14 | 2024-04-09 | 青岛海尔生物科技有限公司 | ITGA6阳性iPSC源小梁网类细胞在制备治疗高眼压疾病药物中的应用及筛选方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4238482A (en) * | 1978-09-29 | 1980-12-09 | Peyman Gholam A | Intraocular infusion irrigation solution and method |
| US5135920A (en) * | 1988-11-16 | 1992-08-04 | Takeda Chemical Industries, Ltd. | Angiostatic agents |
| WO2007002139A2 (en) * | 2005-06-22 | 2007-01-04 | The Trustees Of The University Of Pennsylvania | Neuroprotection of retinal ganglion cells |
| US20140186339A1 (en) * | 2006-10-27 | 2014-07-03 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
| WO2016076780A1 (en) * | 2014-11-11 | 2016-05-19 | Tx Medic Ab | New dextran sulfate |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3705669A1 (de) | 1987-02-21 | 1988-09-01 | Thomae Gmbh Dr K | Verwendung von dextransulfat zur herstellung eines arzneimittels zur behandlung und prophylaxe von gefaessverengungen und gefaessverschluessen |
| JPH02223525A (ja) * | 1988-11-16 | 1990-09-05 | Takeda Chem Ind Ltd | 血管新生阻害剤 |
| US5227372A (en) | 1990-03-07 | 1993-07-13 | Children's Medical Center Corporation | Method for retaining ophthalmological agents in ocular tissues |
| CA2020199C (en) | 1990-06-29 | 2002-08-20 | Daniel Bar-Shalom | Uses of sulphated sugars |
| US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| CA2331620A1 (en) | 1998-05-11 | 1999-11-18 | The Endowment For Research In Human Biology, Inc. | Use of neomycin for treating angiogenesis-related diseases |
| GB9917092D0 (en) | 1999-07-22 | 1999-09-22 | Ml Lab Plc | Treatment of angiogenesis-dependent conditions |
| WO2005110438A2 (en) | 2004-04-15 | 2005-11-24 | Massachusetts Institute Of Technology | Methods and products related to the intracellular delivery of polysaccharides |
| SE0401182D0 (sv) | 2004-05-05 | 2004-05-05 | Q Med Ab | Novel use of a viscoelastic composition |
| US20060154894A1 (en) | 2004-09-15 | 2006-07-13 | Massachusetts Institute Of Technology | Biologically active surfaces and methods of their use |
| US20130273096A1 (en) | 2011-10-05 | 2013-10-17 | Bruce A. Daniels | Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients |
| EP3142684A4 (en) * | 2014-05-12 | 2018-05-23 | Purdue Research Foundation | Selectin and icam/vcam peptide ligand conjugates |
| WO2015190989A1 (en) | 2014-06-12 | 2015-12-17 | Tx Medic Ab | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject |
| SE539575C2 (en) * | 2015-07-30 | 2017-10-17 | Tx Medic Ab | Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis |
| CN107137421A (zh) | 2017-05-25 | 2017-09-08 | 青岛市中心医院 | 硫酸葡聚糖在制备抑制角膜血管新生药物中的应用 |
-
2018
- 2018-05-16 ES ES18727467T patent/ES2777836T3/es active Active
- 2018-05-16 US US16/614,279 patent/US11291684B2/en active Active
- 2018-05-16 CN CN201880031854.2A patent/CN110621320B/zh active Active
- 2018-05-16 EP EP18727467.5A patent/EP3532072B1/en active Active
- 2018-05-16 KR KR1020197033872A patent/KR102331421B1/ko active Active
- 2018-05-16 PT PT187274675T patent/PT3532072T/pt unknown
- 2018-05-16 RU RU2019136633A patent/RU2759998C2/ru active
- 2018-05-16 CA CA3063851A patent/CA3063851C/en active Active
- 2018-05-16 JP JP2019563248A patent/JP6817466B2/ja active Active
- 2018-05-16 DK DK18727467.5T patent/DK3532072T3/da active
- 2018-05-16 PL PL18727467T patent/PL3532072T3/pl unknown
-
2019
- 2019-10-31 IL IL270362A patent/IL270362B/en active IP Right Grant
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4238482A (en) * | 1978-09-29 | 1980-12-09 | Peyman Gholam A | Intraocular infusion irrigation solution and method |
| US5135920A (en) * | 1988-11-16 | 1992-08-04 | Takeda Chemical Industries, Ltd. | Angiostatic agents |
| WO2007002139A2 (en) * | 2005-06-22 | 2007-01-04 | The Trustees Of The University Of Pennsylvania | Neuroprotection of retinal ganglion cells |
| US20140186339A1 (en) * | 2006-10-27 | 2014-07-03 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
| WO2016076780A1 (en) * | 2014-11-11 | 2016-05-19 | Tx Medic Ab | New dextran sulfate |
Non-Patent Citations (1)
| Title |
|---|
| MANCHANDA S et al. Mucoadhesive chitosan-dextran sulfate nanoparticles of acetazolamide for ocular hypertension. Nanotechnol Rev, 2016; 5(5), p. 445-45. * |
Also Published As
| Publication number | Publication date |
|---|---|
| PL3532072T3 (pl) | 2020-09-21 |
| ES2777836T3 (es) | 2020-08-06 |
| EP3532072B1 (en) | 2020-01-01 |
| EP3532072A1 (en) | 2019-09-04 |
| KR102331421B1 (ko) | 2021-11-25 |
| CA3063851C (en) | 2023-09-19 |
| IL270362B (en) | 2021-04-29 |
| BR112019024087A2 (pt) | 2020-06-02 |
| CN110621320A (zh) | 2019-12-27 |
| JP2020519742A (ja) | 2020-07-02 |
| RU2019136633A (ru) | 2021-06-17 |
| KR20200005560A (ko) | 2020-01-15 |
| US20210315920A1 (en) | 2021-10-14 |
| RU2019136633A3 (https=) | 2021-06-17 |
| PT3532072T (pt) | 2020-03-05 |
| US11291684B2 (en) | 2022-04-05 |
| CA3063851A1 (en) | 2018-11-22 |
| JP6817466B2 (ja) | 2021-01-20 |
| CN110621320B (zh) | 2023-03-17 |
| DK3532072T3 (da) | 2020-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yu et al. | Neurokinin-1 receptor antagonism ameliorates dry eye disease by inhibiting antigen-presenting cell maturation and T helper 17 cell activation | |
| Hurst et al. | A novel porcine ex vivo retina culture model for oxidative stress induced by H2O2 | |
| RU2759998C2 (ru) | Лечение глаукомы | |
| JP3973697B2 (ja) | 角膜の保存培養または治療のための神経成長因子の使用 | |
| JP2011513290A (ja) | ＶＥＧＦｘｘｘｂの新規な使用 | |
| He et al. | Association of high-mobility group box-1 with inflammationrelated cytokines in the aqueous humor with acute primary angle-closure eyes | |
| WO2018212708A1 (en) | Treatment of glaucoma | |
| Davani et al. | Choroidal detachment induced by dorzolamide 20 years after cataract surgery | |
| WO2015133459A1 (ja) | 角膜疾患若しくは角膜損傷の予防、抑制又は治療剤、細胞シート、細胞培養補助剤、並びに細胞培養方法 | |
| Monteiro | Liposarcoma of the orbit presenting as an enlarged medial rectus muscle on CT scan | |
| Panda et al. | Corneal tattooing | |
| BR112019024087B1 (pt) | Uso de sulfato de dextrano ou de um sal farmaceuticamente aceitável do mesmo para tratamento, inibição ou prevenção de glaucoma | |
| Gentile et al. | Loss of myelinated retinal nerve fibres in diabetic retinopathy | |
| CN112569338B (zh) | Tdfa在制备预防和/或治疗眼表炎症疾病的药物中的应用 | |
| Pastor Jimeno et al. | Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences | |
| Bajaj et al. | Surgical endoscopic dacryocystorhinostomy | |
| Pinna | Acanthamoeba and disinfecting contact lens solutions | |
| WO2024172043A1 (ja) | 網膜色素上皮裂孔の治療薬 | |
| Taherian et al. | Ultrasound biomicroscopy:“fisherman’s tale” | |
| Trubilin et al. | Safety and efficacy of combined Nd: YAG laser goniopuncture after non-penetrating deep sclerectomy: results of a cohort study | |
| Kokkali | The role of innate immune activation in experimental glaucoma | |
| Paques et al. | Peripheral retinochoroidal anastomosis after central retinal vein occlusion | |
| US20090291887A1 (en) | Proteins of the SDF-1-Family for the Manufacturing of a Medicament | |
| CN119656201A (zh) | 蜗牛粘液提纯物在制备促进角膜上皮损伤愈合的药物中的应用 | |
| Echevarria | The Role of Interleukin-6 in Health and Disease of Retinal Ganglion Cells |